The amyloid-β (Aβ) peptide is a cytotoxic peptide implicated in the pathology of Alzheimer's disease (AD). Catalase and the endoplasmic reticulum Aβ binding dehydrogenase (ERAB) are both inhibited by characterized fragments of the Aβ peptide. In order to target such proteins it is essential to determine which components of these enzymes interact with Aβ. This study reports the use of antisense peptide methodology to identify specific Aβ-binding domains. Synthetic peptides corresponding to the regions of catalase and ERAB identified showed specific binding to Aβ and also prevented Aβ cytotoxicity. Antisense peptide methodology has identified Aβ recognition sequences and may also be applied to the identification of novel Aβ protein interactions to identify targets for use in the treatment of AD.
|Number of pages||6|
|Publication status||Published - 8 Aug 2001|
- Antisense peptide